This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) Compounds of the formula I



I

in which

X = N or CH,

R^1, R^2, R^3 = independently of one another OH, OA, CN, Hal, COR^4 or CH_2R^4,

R^4 = OH, OA, NH_2, NHB or NB_2,

Q = CH_2 or CO,

A, B = independently of one another straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl having 2 to 10 C atoms or alkoxyalkyl having 2 to 10 C atoms,

m = 2, 3, 4, 5 or 6 and

n = 0, 1, 2, 3 or 4,

or physiologically acceptable salts or stereoisomers thereof, including mixtures thereof in all ratios.

2. (Previously Presented) Compounds according to Claim 1 in which

X = N,

R^1, R^2, R^3 = independently of one another CN, OH, COR^4 or CH_2R^4,

R^4 = OH, NH_2, NHB or NHB_2,

Q = CH_2or CO,

B = alkyl having 1-6 C atoms,

m = 4 and

n = 0,

or physiologically acceptable salts or stereoisomers thereof, including mixtures thereof in all ratios.

3. (Currently Amended) A compound ~~according to Claim 1 which is~~of the formula

a) 5-{4-[4-(5-cyano-2,3-dihydro-1H-indol-3-yl)butyl]piperazin-1-yl}benzo-furan-2-carboxamide



~~or~~

b) 5-{4-[4-(5-cyano-2-oxo-2,3-dihydro-1H-indol-3-yl)butyl]piperazin-1-yl}-benzofuran-2-carboxamide



or

c) 5-{4-(5-fluoro-2-oxo-2,3-dihydro-1H-indil-3-yl)butyl]piperazin-1-yl)-benzofuran-2-carboxamide or



.

4. (Previously Presented) Process for the preparation of compounds according to claim 1 or physiologically acceptable salts or stereoisomers thereof, comprising

a) reacting a compound of the formula II, in which R^1, R^2, R^3, X, m and n have the meanings indicated in Claim 1,



II

with dimethyl sulfoxide and concentrated HCl,

or

b) reacting a compound of the formula III, in which R^1, R^2, and n have the meanings indicated in Claim 1, and Y is a halogen or an alcohol provided with protecting groups,



III

with trifluoroacetic acid and triethylsilane and subsequently coupling with a compound of the formula IV, in which R^3, X and n have the meanings indicated in Claim 1



IV,

and reacting with dimethyl sulfoxide and concentrated HCl

or

c) reacting a compound of the formula V, in which R^2 and m have the meanings indicated in Claim 1 and Y is a halogen, or an alcohol provided with protecting groups,



V

with a dehydrating reagent and subsequently coupling with a compound of the formula IV, and reacting with dimethyl sulfoxide and concentrated HCl.

5. (Canceled)

6. (Previously Presented) Pharmaceutical composition comprising at least one compound according to claim 1 and/or physiologically acceptable salts or stereoisomers thereof, including mixtures thereof in all ratios, and a pharmaceutically acceptable carrier.

7. (Previously Presented) Pharmaceutical composition, according to Claim 6 comprising further excipients and/or adjuvants.

8. (Canceled).

9. (Previously Presented) Process for the preparation of a pharmaceutical composition, comprising bringing a compound according to claim 1 and/or one of its physiologically acceptable salts or stereoisomers, including mixtures thereof in all ratios, into a suitable dosage form together with a solid, liquid or semi-liquid excipient or adjuvant.

10. (Canceled)

11. (Canceled)

12. (Currently Amended) A method of achieving an anxiolytic, antidepressant, neuroleptic and/or antihypertonic effect and for treating migraine~~, cerebral infarctions~~ or obsessive compulsive disorder, comprising administering to a host in need thereof an effective amount of a compound according to claim 1 and/or physiologically acceptable salts or stereoisomers thereof, including mixtures thereof in all ratios.

13. (Canceled)

14. (Canceled).

15. (Canceled).